JNJ-26854165 (Serdemetan)

For research use only.

Catalog No.S1172

8 publications

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 137 In stock
EUR 108 In stock
EUR 363 In stock
EUR 953 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's JNJ-26854165 (Serdemetan) has been cited by 8 publications

6 Customer Reviews

  • Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell NEC2O|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46OzJ|NjFOwG0> M332SHNCVkeHUh?=
H4 cell MlnDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlTzTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwME[3NFch|ryP M1ewZ3NCVkeHUh?=
KGN cell M1\WOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnCTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[yNFUh|ryP MkPtV2FPT0WU
786-0 cell NHLZTlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63Nlk5QSEQvF2= MlXXV2FPT0WU
769-P cell NFnYWGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64NlIzPCEQvF2= MkfOV2FPT0WU
K5 cell NWnOcmJxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMU[yOEDPxE1? M4e2bXNCVkeHUh?=
MLMA cell Ml:5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;ycW46UW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB|MkG3JO69VQ>? M3PaWHNCVkeHUh?=
MLMA cell NYjHXGZMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXPFVWVHUW6qaXLpeIlwdiCxZjDoeY1idiCPTF3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQDdyMzFOwG0> M2HwTnNCVkeHUh?=
EW-7 cell NIPYVo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWq0[FBXUW6qaXLpeIlwdiCxZjDoeY1idiCHVz23JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{OjZ7NTFOwG0> Mn\QV2FPT0WU
SW1088 cell MnrUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1PtV2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45ODZ3MTFOwG0> NXjaO4E6W0GQR1XS
MC-IXC cell M17KRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEflZ4ZKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDd5OUKg{txO NWHxNIRYW0GQR1XS
NCI-H2052 cell NVHFe5d6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1;GN2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5yOEG1O{DPxE1? MX3TRW5ITVJ?
IGR-1 cell NXrheIs6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXRUXBNUW6qaXLpeIlwdiCxZjDoeY1idiCLR2KtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTJyMkig{txO MYLTRW5ITVJ?
DSH1 cell MorPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4S3SmlvcGmkaYTpc44hd2ZiaIXtZY4hTFOKMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlQzQTZizszN MUPTRW5ITVJ?
PA-1 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\DRXdKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlMxODV7zszN MoDxV2FPT0WU
SK-MEL-3 cell M4PzPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4TQUGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjNzMkC3JO69VQ>? NULXSocxW0GQR1XS
SW900 cell NX\QdJJtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3nyUmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> NUT1TYFrW0GQR1XS
CAKI-1 cell M2r0d2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI4OzhizszN NIPYO5NUSU6JRWK=
ES1 cell NGD3enpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvMOIY5UW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzQDl5IN88US=> MkPRV2FPT0WU
SK-N-DZ cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUjJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlYzPTl3IN88US=> NXe4WoZyW0GQR1XS
RH-1 cell NHzoNopIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYexeZU{UW6qaXLpeIlwdiCxZjDoeY1idiCUSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QDR4MzFOwG0> NInaeGJUSU6JRWK=
ES8 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zrcWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PVcxOiEQvF2= M1LYTHNCVkeHUh?=
NEC8 cell M1H6O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zh[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|Y6QDJizszN MXnTRW5ITVJ?
LNCaP-Clone-FGC cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEL2fGpKdmirYnn0bY9vKG:oIHj1cYFvKEyQQ3HQMWNtd26nLV\HR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDN3M{[g{txO NFrYfYNUSU6JRWK=
HCE-4 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPnfIp2UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0> M1LlNXNCVkeHUh?=
U-118-MG cell NWq2eoQ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnnmTY5pcWKrdHnvckBw\iCqdX3hckBWNTFzOD3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODFyNk[g{txO M1vheHNCVkeHUh?=
GI-ME-N cell NHf3cHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGdKNU2HLV6gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5Pzl4IN88US=> Ml;RV2FPT0WU
LB1047-RCC cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vnR2lvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMU[xOFMh|ryP NITwbFFUSU6JRWK=
HT-1080 cell M4qxT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH3OUlRKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>? NGHpb5JUSU6JRWK=
NB69 cell M3G2cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm\2TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zOVA1PyEQvF2= M37kNXNCVkeHUh?=
NCI-H1693 cell NWG4W41WT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[5N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDR6OUWg{txO M3XoU3NCVkeHUh?=
HSC-3 cell NVHjS3Z[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWC1Om1OUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDl7M{Og{txO NH;Y[lJUSU6JRWK=
MDA-MB-231 cell Mn;qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnLGTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53NUi5PUDPxE1? MWLTRW5ITVJ?
HOS cell MlXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\DWmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PFY{KM7:TR?= MmjsV2FPT0WU
BT-549 cell M{D3Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{e3RWlvcGmkaYTpc44hd2ZiaIXtZY4hSlRvNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDh5IN88US=> NUnwVXB3W0GQR1XS
NB17 cell NWfPTY5MT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnuPYdQUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0> NULRR2h2W0GQR1XS
5637 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEOxU5dKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc6PjV{IN88US=> MX;TRW5ITVJ?
OVCAR-8 cell MknmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmnSTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OjR|NjFOwG0> NInTT3FUSU6JRWK=
G-402 cell Mnm0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65N|A{PSEQvF2= MVnTRW5ITVJ?
BB30-HNC cell M3zXVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Moj6TY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO M4rHPHNCVkeHUh?=
HCC1806 cell MkX6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFXZToFKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G4NFYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjB6M{O5JO69VQ>? NHPzWnRUSU6JRWK=
COLO-800 cell M4TvXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHDd4EzUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVgxOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMUK2OEDPxE1? NVvKOFFmW0GQR1XS
FADU cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIGxcIhKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM3PTV5IN88US=> NHnSb25USU6JRWK=
NCI-H1651 cell M2PlU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzl2MEmg{txO NGTiNoVUSU6JRWK=
AGS cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHtTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O|EyKM7:TR?= NX;rNo57W0GQR1XS
CHP-212 cell Mmi4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrRfpZKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? M1\XcHNCVkeHUh?=
YAPC cell NX71[ZNOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWf3XoZ[UW6qaXLpeIlwdiCxZjDoeY1idiC\QWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PzdzMTFOwG0> NXHYOVJbW0GQR1XS
GOTO cell M3jmUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFrjTmNKdmirYnn0bY9vKG:oIHj1cYFvKEeRVF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ6PTd4IN88US=> Mm\nV2FPT0WU
KYSE-510 cell M2rQV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1G2ZWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjVzMTFOwG0> NVTMfJlJW0GQR1XS
NCI-H2342 cell NEHEfo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVuwZ|FsUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNlc5KM7:TR?= NF3TRphUSU6JRWK=
BFTC-905 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh|NTFOwG0> NED5RVBUSU6JRWK=
EW-16 cell M{Pobmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGT3e3hKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB7MzFOwG0> NGHUNo5USU6JRWK=
SK-MEL-30 cell NEDUZmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLMPGJYUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke0OVQ{KM7:TR?= MV\TRW5ITVJ?
HLE cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3HkUmlvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63O|Q5QSEQvF2= MVzTRW5ITVJ?
T98G cell MnvJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5OlM2KM7:TR?= NHribmtUSU6JRWK=
HUTU-80 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFXxZnNKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh2MkK4JO69VQ>? MUfTRW5ITVJ?
NOS-1 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1TtS2lvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk1PzZ4IN88US=> NYfo[HllW0GQR1XS
SW780 cell NWfLenh1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3KyWWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=> M2LEXnNCVkeHUh?=
KYSE-180 cell NFPHW5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PzZ3NDFOwG0> MY\TRW5ITVJ?
MDA-MB-361 cell M4PGTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXjmVlFMUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65PFY1PyEQvF2= NVPxcYw{W0GQR1XS
SNU-C2B cell NVXnc3AzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHTiUHlKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT3DNmIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjBzMUO4JO69VQ>? MUXTRW5ITVJ?
NCI-H661 cell NGXFZohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PQVGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO MkTFV2FPT0WU
OE33 cell NV75bGR3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF61RYZKdmirYnn0bY9vKG:oIHj1cYFvKE:HM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE1Ozh7IN88US=> NV;nT5Y2W0GQR1XS
TYK-nu cell NVnKcXJrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHfqdJlKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjF6NkOg{txO NIiyfIlUSU6JRWK=
COLO-792 cell MorMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0> M2jZOXNCVkeHUh?=
HEL cell MkHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMk[3OkDPxE1? MoSzV2FPT0WU
D-566MG cell NYjLVHdVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV3IU2dxUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|M{S5NUDPxE1? NHLsOnRUSU6JRWK=
U031 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWXFO25TUW6qaXLpeIlwdiCxZjDoeY1idiCXMEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OThzNjFOwG0> NX;Ic3hIW0GQR1XS
COR-L23 cell MnvkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{OzR4IN88US=> M2L3PHNCVkeHUh?=
NCI-H2452 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmLDTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK0OVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjV{MkixJO69VQ>? NEHBWJJUSU6JRWK=
BB65-RCC cell NVTYZpo4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PDV7IN88US=> NIf5O5JUSU6JRWK=
CAL-33 cell M3rRdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mni5TY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PjZ3IN88US=> M4eySHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / HDM2 / HDMX / p21 / Noxa / Puma ; 

PubMed: 20736344     


OCI-AML-3 and MOLM-13 cells were incubated with a range of concentrations of JNJ-26854165 for 18 hours.

ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR ; 

PubMed: 23820125     


U266 and JeKo-1 cells were treated with JNJ-26854165 and cells harvested at the indicated time points.

MDM2 / p-MDM2 / p53 ; 

PubMed: 27999193     


K562 cells was harvested at 48 h after treatment with various JNJ-165 concentrations, and then nuclear and cytoplasmic extracts were prepared to check the levels of p53, MDM2 and p-MDM2 by Western blotting. Actin and LaminB were used as loading control respectively.

Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3 ; 

PubMed: 27999193     


CML cell lines were treated with JNJ-165 at the indicated doses for 48 h. Whole-cell lysates were extracted to assess the levels of BCR-ABL and phosphorylated (p)-BCR-ABL (Tyr177), and then were analyzed for BCR-ABL downstream signaling mediators p-CrkL (Try207), total Stat5, p-Stat5 (Tyr694), total Stat3, and p-Stat3 (Ser727) expression by Western blot analysis. The expression of β-actin was used as loading control. The data are representative of three determinations with identical results.

20736344 23820125 27999193
Growth inhibition assay
Cell viability; 

PubMed: 23820125     


MCL (B) and MM (C) cell lines were seeded in 96-well plates for viability analyses using WST-1 and treated with JNJ-26854165 for 72 hours. Results are expressed as the percentage of cell viability in relation to the vehicle-treated sample for each cell line, which was arbitrarily set at 100%

23820125
Immunofluorescence
p53; 

PubMed: 27999193     


Two-color fluorescence microscope analysis of antibody against p53 protein (green) and nuclei (DAPI staining, blue) showed nuclear accumulation of p53 in K562 cells with treatment of 1 μM JNJ-165, but not in control-treated cells after 48 h. Images were taken on a fluorescence microscopy (100×).

27999193
In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: CB17SC scid-/- female mice.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID